Rare disease patients in Europe face significant indirect costs beyond the price of treatment. These hidden costs include caregiver burden, lost productivity due to illness or caregiving responsibilities, home modifications, and travel expenses for specialized care. These indirect costs can be substantial, particularly when treatment is unavailable, and often fall on families, further straining their financial and emotional resources. Addressing these indirect costs is crucial for improving the overall quality of life for rare disease patients and their families. How can we as Market Access professionals help?
In this presentation you will learn:
- How to raise awareness and educate both doctors and patients?
- How to ensure patients are diagnosed correctly?
- Will JCA help or harm?
&nsbp;
